Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C. (Q53142953)
Jump to navigation
Jump to search
scientific article published on 29 October 2011
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C. |
scientific article published on 29 October 2011 |
Statements
Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C. (English)
T J Price
D Zannino
K Wilson
R J Simes
J Cassidy
G A Van Hazel
A Broad
V Ganju
S P Ackland
N C Tebbutt
29 October 2011
23
6
1531-1536
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference